AstraZeneca (AZN) Shares Decline After Recruitment Paused in Head and Neck Cancer Trial

October 27, 2016 10:58 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

(Updated - October 27, 2016 11:44 AM EDT)

(Updated - October 27, 2016 11:13 and 11:27 AM EDT)

AstraZeneca (NYSE: AZN) declined Thursday, falling over 4% intraday. Chatter suggested weakness was related to a halt in recruitment for its trial evaluating its IO combo in head and neck cancer.


Recruitment was suspended in its study of MEDI4736 (Durvaluma) Monotherapy in Combination with Tremelimumab, according to In a statement to Bloomberg an AstraZeneca spokesperson confirmed it paused enrollment for some Durvalumab trials over bleeding incidents.


Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer

This study has suspended participant recruitment.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: February 18, 2015
Last updated: October 20, 2016
Last verified: October 2016

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Hot Corp. News, Hot FDA News, Trader Talk

Add Your Comment